Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | VCP | P55072 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CISD2 | Q8N5K1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945236 | 0.88 | BACE1 (0.54) | BACE1 | |
| SCHEMBL7940504 | 0.86 | PTGDR2 (0.40) | BACE1F10PDGFRBKDRCISD2 | |
| SCHEMBL7943409 | 0.82 | RAB9A (0.45) | BACE1PRKCI | |
| SCHEMBL7935757 | 0.80 | RAB9A (0.50) | BACE1PRKCIF10VCP | |
| SCHEMBL7932770 | 0.78 | BACE1 (0.45) | BACE1PRKCIVCPPDGFRBKDR | |
| SCHEMBL7944983 | 0.78 | BACE1 (0.45) | BACE1PRKCIVCPKITBRAF | |
| SCHEMBL7935620 | 0.78 | BACE1 (0.53) | BACE1PRKCI | |
| SCHEMBL7935774 | 0.76 | BACE1 (0.43) | BACE1PRKCIVCPPDGFRBKDR | |
| SCHEMBL12445797 | 0.76 | F10 (0.34) | PRKCIF10CISD2 | |
| SCHEMBL7945397 | 0.75 | BACE1 (0.49) | BACE1PRKCIVCPKITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885PRKCI 2747/4885F10 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.